Pathologists Need Better Reporting Guidelines for Postneoadjuvant Chemotherapy Specimens
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment.
Renal Cell Carcinoma
RENAL CELL CARCINOMA ADVISOR
FEATURED CONTENT
-
-
Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated
As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap. -
The DYSF Gene and Renal Cell Carcinoma: A New Prognostic Biomarker?
There is great interest in evaluating the link between hypercalcemia and prognosis in ccRCC by researching the genes that influence calcium levels. -
Knowing the Appropriateness of Running Noninferiority Trials in Oncology
Researches took a critical look at noninferiority trials and determined that when a new intervention is “not worse,” the possibility exists that it is not better, either. -
Tapping Into the Therapeutic Expertise of High-Volume Cancer Centers
Researchers examine how patient outcomes could be affected if patients were to receive systemic drug treatment at dedicated cancer centers versus at community health systems.
VIDEO SERIES
Tivozanib for RCC
Genitourinary Oncology: A Peek Over the Horizon
Immunotherapy of Renal Cell Carcinoma
Targeted Therapies for Renal Cell Carcinoma
Genetics and Heterogeneity
Genetic Predisposition to Kidney Cancers
Personalized Medicines for Kidney Cancers
Drugs in the Pipeline
Resistance to Therapy Among Kidney Cancers
Targeted Therapy
The Role of Neoadjuvant Tx
Sx Options – Ablative Techniques
Sx Options – Lymph Node
Sx Options – Cytoreductive Nephrectomy
TKIs – First-Line Therapy
TKIs – Second-Line Therapy
Biomarkers in RCC
The MET Pathway
Checkpoint Inhibitors
RENAL CELL CARCINOMA NEWS
RCC With Isolated Lymph Node Metastases Has Poor Prognosis After Surgery
Adjuvant Sorafenib Does Not Improve Survival in Renal Cell Carcinoma
Longer Duration of Steroids May Affect Outcomes During Anti-PD-1 Treatment
Should Age Be a Barrier to Clinical Trial Participation for Older Patients With Metastatic Renal Cell Carcinoma?
CheckMate 214: Long-Term Results Confirm Superiority of Nivolumab Plus Ipilimumab for mRCC
Want to read more?
Please login or register first to view this content.
Next post in Renal Cell Carcinoma
